Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder From a Modified Manufacturing Process (TIPnew).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tobramycin (Primary)
Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
Focus Registrational; Therapeutic Use
Acronyms EDIT
Sponsors Novartis

27 Oct 2011 Additional lead trial centre identified as reported by Clinical Trials Registry - India record.
07 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
07 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.(NCT00918957).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com